Not Many Are Piling Into Sundaram Multi Pap Limited (NSE:SUNDARAM) Just Yet

There wouldn't be many who think Sundaram Multi Pap Limited's (NSE:SUNDARAM) price-to-sales (or "P/S") ratio of 0.9x is worth a mention when the median P/S for the Forestry industry in India is very similar. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.

Check out our latest analysis for Sundaram Multi Pap

How Sundaram Multi Pap Has Been Performing

We'd have to say that with no tangible growth over the last year, Sundaram Multi Pap's revenue has been unimpressive. One possibility is that the P/S is moderate because investors think this benign revenue growth rate might not be enough to outperform the broader industry in the near future. If not, then existing shareholders may be feeling hopeful about the future direction of the share price.

Although there are no analyst estimates available for Sundaram Multi Pap, take a look at this free data-rich visualisation to see how the company stacks up on earnings, revenue and cash flow.

How Is Sundaram Multi Pap's Revenue Growth Trending?

The only time you'd be comfortable seeing a P/S like Sundaram Multi Pap's is when the company's growth is tracking the industry closely.

Retrospectively, the last year delivered virtually the same number to the company's top line as the year before. Although pleasingly revenue has lifted 127% in aggregate from three years ago, notwithstanding the last 12 months. Therefore, it's fair to say the revenue growth recently has been great for the company, but investors will want to ask why it has slowed to such an extent.

This is in contrast to the rest of the industry, which is expected to grow by 8.0% over the next year, materially lower than the company's recent medium-term annualised growth rates.

With this information, we find it interesting that Sundaram Multi Pap is trading at a fairly similar P/S compared to the industry. Apparently some shareholders believe the recent performance is at its limits and have been accepting lower selling prices.

The Bottom Line On Sundaram Multi Pap's P/S

We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

We didn't quite envision Sundaram Multi Pap's P/S sitting in line with the wider industry, considering the revenue growth over the last three-year is higher than the current industry outlook. There could be some unobserved threats to revenue preventing the P/S ratio from matching this positive performance. At least the risk of a price drop looks to be subdued if recent medium-term revenue trends continue, but investors seem to think future revenue could see some volatility.

Plus, you should also learn about this 1 warning sign we've spotted with Sundaram Multi Pap.

If you're unsure about the strength of Sundaram Multi Pap's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.